Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
← catalyst calendarNCT06700343 · readout in 243 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
152actual
Sites
109
Countries
Belgium, Bulgaria, Canada +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-13 | actual | When the study began enrolling |
| Primary completion | 2027-04-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-04 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
- Drug: Ocrelizumab (US)
- Drug: Ocrelizumab (EU)
- Drug: ABP 692
Primary outcomes
what the primary-completion date above is the date OFArea Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP)
measured Day 1 to Day 15
AUC From Time 0 Extrapolated toInfinity (AUC0-inf) of the Entire Initial Dose of IP
measured Day 1 to Week 16
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed